HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $36.
July 01, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $36.
The reiteration of a Buy rating and the maintenance of a $36 price target by a reputable analyst can boost investor confidence in Verona Pharma, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100